NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The FDA throws out the company’s second attempt at an accelerated approval.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
